Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Share-based Compensation (2016 - 2026)

Insight Molecular Diagnostics' Share-based Compensation history spans 6 years, with the latest figure at $721000.0 for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 44.49% to $721000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 26.58% increase, with the full-year FY2025 number at $2.2 million, up 26.58% from a year prior.
  • Share-based Compensation hit $721000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $521000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for IMDX hit a ceiling of $3.2 million in Q3 2022 and a floor of $386000.0 in Q2 2024.
  • Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $777500.0 in 2023.
  • Biggest five-year swings in Share-based Compensation: soared 73.1% in 2021 and later plummeted 81.52% in 2023.
  • Tracing IMDX's Share-based Compensation over 5 years: stood at $1.7 million in 2021, then skyrocketed by 53.61% to $2.6 million in 2022, then plummeted by 81.52% to $484000.0 in 2023, then grew by 3.1% to $499000.0 in 2024, then soared by 44.49% to $721000.0 in 2025.
  • Business Quant data shows Share-based Compensation for IMDX at $721000.0 in Q4 2025, $521000.0 in Q3 2025, and $504000.0 in Q2 2025.